FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
about
Sphingolipids: a potential molecular approach to treat allergic inflammationThe emerging role of FTY720 (Fingolimod) in cancer treatmentLeptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemmaEvolving concepts in cancer therapy through targeting sphingolipid metabolismIn vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibodyFTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levelsNatural products as sources of new drugs over the 30 years from 1981 to 2010Sphingolipid modulation of angiogenic factor expression in neuroblastoma.Cellular characterization of ultrasound-stimulated microbubble radiation enhancement in a prostate cancer xenograft model.Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potentialCombination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.Sphingosine kinase 1 in cancer.Advances in the management of peritoneal mesotheliomaInterdiction of sphingolipid metabolism to improve standard cancer therapies.Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathwayTumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind HydeDevelopment of small-molecule inhibitors of sphingosine-1-phosphate signalingSphingosine kinase 1 as an anticancer therapeutic target.Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer.Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer.Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progressionFTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathwaySphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPβ and potentiates breast cancer progression.The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells.Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1.Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.Targeting sphingosine-1-phosphate signaling for cancer therapy.Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells.
P2860
Q21296721-40DE7435-1B5A-46B4-93D6-2D69BCA65E3FQ26748927-2E28F029-C61F-4EC3-995B-E25A80B977CBQ26786149-4CCE859B-0954-4181-BF70-41DCE584C535Q26863646-B537AB3E-7271-4362-82D1-33C507EA0321Q28482145-AF36D647-0412-4D8A-9A96-CFD25C03837EQ28541065-A0B080BA-CC58-4C64-B963-34AA0A225752Q29616640-CEC47F57-02F0-4145-BA7B-F3823CB56F31Q30425699-B038929A-EDE4-4163-BB82-6E6196198FC6Q30441894-90E4AFBE-DF12-46ED-834A-C45364A5D5E9Q33618473-C5831007-4C6E-4B9B-8631-3A020A15A78AQ33795328-0B47FC67-42D4-4406-A467-EE7DD3D390E8Q33799125-02A55733-9B9D-4F4C-811E-E3B2AAFDBF5DQ33853998-FBAB9E76-BBB1-4D21-A762-FBB6839CC81FQ34137322-E81809D8-23D4-4662-AEBB-D6E129BC4DA4Q34373466-4F333FA2-DC89-49BE-A20E-10535EBD9CDAQ35000226-FC70A3D0-4E35-41B4-B1FC-693FE4691406Q35264010-163B1E6B-9957-4187-BFB8-825B7597294AQ35489007-E2F28923-E773-4016-A6BD-8FD6C56B557DQ35794452-C46F28EE-69D9-48EB-863D-B2FB3D4E4C9AQ35817821-D83A7EB0-1793-4ACF-957A-48678C171B58Q35955451-5CF83813-C96E-41E7-BAEC-789064F9B5F0Q36602177-32C30863-2DB5-4AF2-A1AD-724D7079DB0FQ36748690-BB0CBF63-6673-4995-9D4C-4B841A08D44CQ36772101-838A4089-D253-484D-B222-52927ABBB0D5Q37114962-31A9D028-89A4-4A3A-AB96-E6FB13958320Q37697046-B6FF5CC5-18F5-43FB-84EF-3F0E1CB5C8FDQ37930972-447E4E12-E7D7-4110-A30F-EDEF6DFA4409Q38447666-F27372EB-926A-4098-9FE5-6BEA56C8CE5EQ38546700-E1750CF6-2225-4524-880E-CE61EED79B0FQ38607090-1637B8C1-402C-41CF-B324-2AC4111C145CQ38640378-22E48945-C3F0-43E3-BC88-66C00E2FDD02Q38890714-3F972701-D10B-44F6-943F-84A8CED901C3Q38909416-3EA24560-2EC2-48E9-8AB4-03EA582939B7Q38943724-96F36EDF-DD08-4A14-B192-F0F014C09F05Q38990892-7D3180D5-6C21-4222-81AD-B850180A2494Q39001159-3E324B7D-CDC4-44C6-8E87-B6FCEF1127E0Q39088175-8DD6579F-DD10-43FC-9407-0143DA70B4AEQ39207332-85F891EF-15C6-4459-A4EA-6ABD9618420DQ39379449-A0F10A6D-817B-4F7D-A145-0D3D7D8C8E6AQ39394808-CD50FEF2-AD05-4638-9047-D94389B8558D
P2860
FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
FTY720 (fingolimod) sensitizes ...... ition of sphingosine kinase-1.
@en
type
label
FTY720 (fingolimod) sensitizes ...... ition of sphingosine kinase-1.
@en
prefLabel
FTY720 (fingolimod) sensitizes ...... ition of sphingosine kinase-1.
@en
P2093
P50
P1433
P1476
FTY720 (fingolimod) sensitizes ...... bition of sphingosine kinase-1
@en
P2093
Bernard Malavaud
Jonathan Waxman
Leyre Brizuela
Lysann Sauer
Muriel Golzio
Nicolas Doumerc
Torsten Bohler
Vishal Salunkhe
P304
P356
10.1158/0008-5472.CAN-10-1388
P407
P577
2010-10-19T00:00:00Z